Loading…
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $607M | $-41M | $-226M | $-191M | -17.8% | -14.9% | - |
| 2024 | $713M | $135M | $-53M | $-208M | -3.9% | -17.4% | - |
| 2023 | $863M | $-66M | $-189M | $-44M | -13.6% | -14.0% | - |
| 2022 | $1.0B | $-271M | $-328M | $-120M | -21.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1,004.20 | 863.50 | 713.14 | 606.88 |
| Cost Of Revenue | 715.98 | 545.37 | 494.63 | 400.94 |
| Gross Profit | 288.22 | 318.13 | 218.51 | 205.94 |
| Operating Expense | 534.34 | 476.18 | 492.07 | 424.93 |
| Operating Income | -246.12 | -158.06 | -273.56 | -218.99 |
| EBITDA | -270.81 | -65.52 | 135.28 | -41.27 |
| EBIT | -379.46 | -170.81 | 37.10 | -132.90 |
| Pretax Income | -391.52 | -184.32 | -10.36 | -241.36 |
| Tax Provision | -63.50 | 4.44 | 42.84 | -15.71 |
| Net Income | -328.40 | -188.86 | -53.22 | -225.68 |
| Net Income Common Stockholders | -328.40 | -188.86 | -53.22 | -225.68 |
| Total Expenses | 1,250.32 | 1,021.55 | 986.70 | 825.86 |
| Interest Expense | 12.06 | 13.51 | 47.47 | 108.46 |
| Interest Income | 1.98 | 3.98 | 8.43 | 14.81 |
| Research And Development | 73.89 | 89.59 | 105.21 | 124.03 |
| Selling General And Administration | 372.67 | 300.56 | 304.22 | 223 |
| Normalized EBITDA | -291.33 | -65.77 | 39.95 | -142.42 |
| Normalized Income | -345.60 | -189.06 | -128.54 | -320.24 |
| Basic EPS | -0.46 | -0.25 | -0.08 | -0.30 |
| Diluted EPS | -0.46 | -0.25 | -0.08 | -0.30 |
| Tax Effect Of Unusual Items | 3.32 | 0.05 | 20.02 | 6.58 |
| Tax Rate For Calcs | 0.16 | 0.21 | 0.21 | 0.07 |
| Total Unusual Items | 20.52 | 0.26 | 95.33 | 101.15 |
| Total Unusual Items Excluding Goodwill | 20.52 | 0.26 | 95.33 | 101.15 |
| Net Income From Continuing Operation Net Minority Interest | -328.40 | -188.86 | -53.22 | -225.68 |
| Reconciled Depreciation | 108.66 | 105.30 | 98.18 | 91.63 |
| Reconciled Cost Of Revenue | 695.11 | 526.10 | 479.09 | 387.20 |
| Net Interest Income | -10.07 | -9.52 | -39.04 | -93.65 |
| Net Income From Continuing And Discontinued Operation | -328.40 | -188.86 | -53.22 | -225.68 |
| Total Operating Income As Reported | -226.25 | -157.02 | -152.06 | -117.41 |
| Diluted Average Shares | 719.06 | 751.72 | 694.02 | 751.13 |
| Basic Average Shares | 719.06 | 751.72 | 694.02 | 751.13 |
| Diluted NI Availto Com Stockholders | -328.40 | -188.86 | -53.22 | -225.68 |
| Net Income Including Noncontrolling Interests | -328.40 | -188.86 | -53.22 | -225.68 |
| Net Income Continuous Operations | -328.40 | -188.86 | -53.22 | -225.68 |
| Earnings From Equity Interest Net Of Tax | -0.38 | -0.11 | -0.02 | -0.03 |
| Other Income Expense | -135.32 | -16.74 | 302.24 | 71.27 |
| Other Non Operating Income Expenses | -155.84 | -16.99 | 206.90 | -29.88 |
| Special Income Charges | 19.87 | 1.04 | 121.49 | 101.58 |
| Gain On Sale Of Ppe | 18.56 | 0 | 121.49 | 101.58 |
| Write Off | 0 | 0 | 0 | 0 |
| Restructuring And Mergern Acquisition | -1.31 | -1.04 | 0 | 0 |
| Gain On Sale Of Security | 0.65 | -0.78 | -26.16 | -0.43 |
| Net Non Operating Interest Income Expense | -10.07 | -9.52 | -39.04 | -93.65 |
| Interest Expense Non Operating | 12.06 | 13.51 | 47.47 | 108.46 |
| Interest Income Non Operating | 1.98 | 3.98 | 8.43 | 14.81 |
| Depreciation Amortization Depletion Income Statement | 87.78 | 86.03 | 82.63 | 77.89 |
| Depreciation And Amortization In Income Statement | 87.78 | 86.03 | 82.63 | 77.89 |
| Amortization | 87.78 | 86.03 | 82.63 | 77.89 |
| Amortization Of Intangibles Income Statement | 87.78 | 86.03 | 82.63 | 77.89 |
| Operating Revenue | 1,004.20 | 863.50 | 713.14 | 606.88 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OPKO Health, Inc.this co. | OPK | $838M | - | 0.66 | -17.8% | -7.47 |
| SELLAS Life Sciences Group, Inc. | SLS | $862M | - | 10.09 | -37.9% | - |
| Janux Therapeutics, Inc. | JANX | $860M | - | 0.89 | -11.9% | 0.55 |
| EVMN | EVMN | $859M | - | 3.66 | -33.5% | -8.93 |
| Theravance Biopharma, Inc. | TBPH | $859M | 8.09 |
| 2.87 |
| 35.7% |
| -296.42 |
| MannKind Corporation | MNKD | $849M | 137.50 | -16.57 | -11.5% | 19.49 |
| Omada Health, Inc. | OMDA | $841M | - | 3.60 | -5.6% | -94.35 |
| MeiraGTx Holdings plc | MGTX | $828M | - | -126.06 | 1971.4% | -8.05 |
| First Tracks Biotherapeutics, Inc. | TRAX | $821M | - | - | -41.8% | - |
| Peer Median | - | 72.80 | 2.87 | -11.7% | -8.49 | |